2020
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints
Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, Clump DA, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, Skinner HD. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. International Journal Of Radiation Biology 2020, 97: 1121-1128. PMID: 32073931, PMCID: PMC7483862, DOI: 10.1080/09553002.2020.1730014.Peer-Reviewed Original ResearchConceptsHPV statusHPV(-) cellsNeck cancerPARP inhibitionPCR arrayDNA repair genesSignificant radiosensitizationBeneficial treatment optionPARP inhibitor niraparibEffective treatment strategiesHNSCC cell linesNormal tissue toxicityRepair genesShRNA screenRole of p16HPV- tumorsHNSCC xenograftsTreatment optionsTreatment modalitiesTreatment strategiesTherapeutic ratioLimited progressionHPVP16 expressionNiraparib
2019
Variations in HPV function are associated with survival in squamous cell carcinoma
Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 2019, 4: e124762. PMID: 30626753, PMCID: PMC6485353, DOI: 10.1172/jci.insight.124762.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaCell carcinomaTreatment responseLong-term survival ratesHPV-related cancersRadiotherapy-related morbiditySubset of patientsPoor treatment responseNew therapeutic approachesSubset of tumorsPrognostic biomarker signaturesTreatment deintensificationHPV positivityOPSCC patientsHPV- tumorsStandard therapyPoor outcomeCervical carcinomaClinical similaritiesHPV biologyTherapeutic approachesIndependent cohortPatient stratificationSurvival rate